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Coupling of liquid chromatography to mass spectrometry (LC-MS) represents 
a near-ideal analytical tool for drug bioanalysis. This instrumentation allows 
identification and quantification with high selectivity and sensitivity, and provides 
information on the structure of tested compounds. An integral part of bioanalytical 
methods is the sample treatment prior to analysis, which should include isolation of the 
analytes, remove ballast from the matrix and ideally preconcentrate the sample. 
The sample treatment should be effective, quick, simple and repeatable. Current trends 
also emphasis process automation, high throughput and low consumption of organic 
solvent, which is in accordance with green chemistry. 
Dexrazoxane (DEX) is the only approved, clinically used drug, preventing chronic 
cumulative cardiotoxicity caused by anthracycline (ANT) therapy – commonly used 
anticancer drugs. The development of novel and more effective cardioprotective drugs 
is limited by uncertainties regarding (1) information about the pathophysiological 
mechanism of chronic ANT cardiotoxicity (2) the mechanism of action of DEX and 
(3) the structure-cardioprotective activity relationship of bisdioxopiperazines.  
The theoretical part of this dissertation focused on utilization of LC-MS 
instrumentation in drug bioanalysis, on conventional sample treatment methods, 
on current trends in microextraction and their application in bioanalysis. Furthermore, 
validation guidelines for bioanalysis are discussed and, finally, the analyzed substances 
are presented. The experimental part is conceived as a commentary on four published 
articles. This part is divided into two thematic units: (1) bioanalytical evaluation of new 
 
 
potential cardioprotectives – dexrazoxane analogues and (2) development and 
optimization of microextraction techniques for isolation of anthracyclines from rabbit 
plasma. 
In the first part, bioanalysis of new DEX analogues and prodrugs, and their 
cardioprotective potential against ANT-induced toxicity was examined. The LC-MS 
methods for analysis of new DEX analogues and their potential prodrugs have been 
developed and validated in relevant biological matrices. The methods were utilized for 
in vitro stability, bioactivation and metabolism studies, and for determination 
of phramacockinetics in vivo.  We revealed a very close structure-cardioprotective 
activity relationship in bisdioxopiperazine group. Furthermore, selected DEX analogs 
were characterized in terms of stability, metabolism and bioactivation. And finally, 
we discovered a promising drug candidate for further comprehensive in vivo 
examinations on chronic ANT-cardiotoxicity model. 
The second part focused on determination of ANT in rabbit plasma using liquid 
phase microextraction methods (LPME). A 96-well LPME and electromembrane 
extraction (EME) were both tested. The optimized EME was subsequently compared with 
conventional extraction techniques, namely with protein precipitation and liquid-liquid 
extraction. The EME outperformed the conventional methods in all tested parameters, 
which included recovery, matrix effects and purification of the sample evaluated 
by the phospholipid content. In this work an alternative microextraction method for 
isolation of anthracyclines from plasma was developed. The EME proved to be fast, 
efficient, reliable and a green technique. 
